poisar

Stock

Immunovant, Inc. IMVT

$41.82+0.00%

Overview

IMVT market data

Price History

IMVT price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$2.77
Diluted earnings per share over the trailing twelve months.
Beta
0.82
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$14.47 – $42.92
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $8.6B · P/B 5.93.

Company News

10 captured
8-K filing — Immunovant, Inc. (IMVT)SEC EDGAR · Aug 6, 2026, 11:15 AM
Immunovant Q1 EPS $(0.75) Misses $(0.61) EstimateBenzinga · Aug 6, 2026, 11:01 AM
JP Morgan Maintains Overweight on Immunovant, Raises Price Target to $50Benzinga · Aug 4, 2026, 6:40 PM
Citigroup Maintains Buy on Immunovant, Raises Price Target to $61Benzinga · Jun 30, 2026, 6:55 PM
Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsightGlobenewswire Inc · Jun 22, 2026, 5:15 PM
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsightGlobenewswire Inc · Jun 2, 2026, 5:15 PM
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For TuesdayBenzinga · May 26, 2026, 1:09 PM
Guggenheim Maintains Buy on Immunovant, Raises Price Target to $62Benzinga · May 26, 2026, 12:56 PM
Truist Securities Maintains Hold on Immunovant, Raises Price Target to $30Benzinga · May 22, 2026, 3:45 PM
These Analysts Increase Their Forecasts On Immunovant After Q4 ResultsBenzinga · May 21, 2026, 4:10 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock